Advertisement
BIIB vs HBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and HBIO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileHBIO’s FA Score has 1 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- HBIO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 5 TA indicator(s) are bullish while HBIO’s TA Score has 4 bullish TA indicator(s).
- BIIB’s TA Score: 5 bullish, 2 bearish.
- HBIO’s TA Score: 4 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +4.69% price change this week, while HBIO (@Medical Specialties) price change was -11.51% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.13%. For the same industry, the average monthly price growth was +2.56%, and the average quarterly price growth was +9.33%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.93%. For the same industry, the average monthly price growth was +1.81%, and the average quarterly price growth was -0.17%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
HBIO is expected to report earnings on Aug 06, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+1.13% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Medical Specialties (+1.93% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIIB | HBIO | BIIB / HBIO | |
| Capitalization | 31.3B | 184M | 17,011% |
| EBITDA | 2.04B | 8.03M | 25,370% |
| Gain YTD | -13.111 | -78.531 | 17% |
| P/E Ratio | 26.95 | N/A | - |
| Revenue | 9.84B | 112M | 8,782% |
| Total Cash | 1.05B | 4.28M | 24,516% |
| Total Debt | 7.34B | 42.8M | 17,145% |
BIIB | HBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 71 | 99 | |
PRICE GROWTH RATING 1..100 | 62 | 65 | |
P/E GROWTH RATING 1..100 | 96 | 2 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIIB's Valuation (88) in the Biotechnology industry is in the same range as HBIO (100). This means that BIIB’s stock grew similarly to HBIO’s over the last 12 months.
BIIB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HBIO (100). This means that BIIB’s stock grew similarly to HBIO’s over the last 12 months.
BIIB's SMR Rating (71) in the Biotechnology industry is in the same range as HBIO (99). This means that BIIB’s stock grew similarly to HBIO’s over the last 12 months.
BIIB's Price Growth Rating (62) in the Biotechnology industry is in the same range as HBIO (65). This means that BIIB’s stock grew similarly to HBIO’s over the last 12 months.
HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for BIIB (96). This means that HBIO’s stock grew significantly faster than BIIB’s over the last 12 months.
| BIIB | HBIO | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 64% |
| Stochastic ODDS (%) | 1 day ago 62% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 58% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 47% | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 55% | 1 day ago 74% |
| Advances ODDS (%) | 2 days ago 54% | 2 days ago 73% |
| Declines ODDS (%) | 4 days ago 70% | 4 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 50% | 3 days ago 67% |
| Aroon ODDS (%) | 1 day ago 33% | N/A |
Advertisement
BIIB and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | -0.24% | ||
| AMGN - BIIB | 55% Loosely correlated | +0.47% | ||
| PFE - BIIB | 49% Loosely correlated | +0.24% | ||
| SNY - BIIB | 47% Loosely correlated | -2.05% | ||
| NVS - BIIB | 45% Loosely correlated | -1.54% | ||
| GSK - BIIB | 44% Loosely correlated | -0.86% | ||
More | ||||
HBIO and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.
| Ticker / NAME | Correlation To HBIO | 1D Price Change % | ||
|---|---|---|---|---|
| HBIO | 100% | +1.03% | ||
| IRMD - HBIO | 53% Loosely correlated | +0.42% | ||
| ICUI - HBIO | 38% Loosely correlated | -0.54% | ||
| A - HBIO | 37% Loosely correlated | +0.60% | ||
| ANGO - HBIO | 35% Loosely correlated | +2.02% | ||
| NOTV - HBIO | 35% Loosely correlated | +3.21% | ||
More | ||||